Search research articles
Contact Us
Filters
Showing results (1-10 of 34) with videos related to
Page
of 4
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
January 3, 2007
Carisbamate (RWJ-333369)
Gerald P Novak, Michael Kelley, Peter Zannikos, et al.
Journal of Clinical Pharmacology
|
October 21, 2011
Effect of carisbamate on the pharmacokinetics and pharmacodynamics of warfarin in healthy participants
Martha Gonzalez, Peter Zannikos, Allitia DiBernardo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
May 14, 2010
Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma
Wenying Jian, Richard Edom, Naidong Weng, et al.
Epilepsy & Behavior : E&B
|
August 19, 2011
Cognitive effects of carisbamate in randomized, placebo-controlled, healthy-volunteer, multidose studies
Kimford J Meador, H R Brashear, Frank Wiegand, et al.
Clinical Drug Investigation
|
November 18, 2016
Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach
Liping Zhang, Xiaoyu Yan, Sayori Nobe, et al.
Epilepsy Research
|
February 19, 2008
Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly
Rene Levy, Isabelle Ragueneau-Majlessi, Bhavna Solanki, et al.
Clinical Pharmacokinetics
|
May 17, 2022
Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model
Marie-Emilie Willemin, Peter Zannikos, Geert Mannens, et al.
Journal of Clinical Pharmacology
|
May 14, 2011
Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate
Kenneth Moore, Peter Zannikos, Bhavna Solanki, et al.
Clinical Pharmacokinetics
|
July 4, 2023
Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment
Peter Zannikos, Bhavna Solanki, Marc De Meulder, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2006
Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib
Juan Jose Perez-Ruixo, Peter Zannikos, Vural Ozdemir, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 34) with videos related to
Sort By:
Page
of 4
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
January 3, 2007
Carisbamate (RWJ-333369)
Gerald P Novak, Michael Kelley, Peter Zannikos, et al.
Journal of Clinical Pharmacology
|
October 21, 2011
Effect of carisbamate on the pharmacokinetics and pharmacodynamics of warfarin in healthy participants
Martha Gonzalez, Peter Zannikos, Allitia DiBernardo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
May 14, 2010
Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma
Wenying Jian, Richard Edom, Naidong Weng, et al.
Epilepsy & Behavior : E&B
|
August 19, 2011
Cognitive effects of carisbamate in randomized, placebo-controlled, healthy-volunteer, multidose studies
Kimford J Meador, H R Brashear, Frank Wiegand, et al.
Clinical Drug Investigation
|
November 18, 2016
Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach
Liping Zhang, Xiaoyu Yan, Sayori Nobe, et al.
Epilepsy Research
|
February 19, 2008
Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly
Rene Levy, Isabelle Ragueneau-Majlessi, Bhavna Solanki, et al.
Clinical Pharmacokinetics
|
May 17, 2022
Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model
Marie-Emilie Willemin, Peter Zannikos, Geert Mannens, et al.
Journal of Clinical Pharmacology
|
May 14, 2011
Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate
Kenneth Moore, Peter Zannikos, Bhavna Solanki, et al.
Clinical Pharmacokinetics
|
July 4, 2023
Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment
Peter Zannikos, Bhavna Solanki, Marc De Meulder, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2006
Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib
Juan Jose Perez-Ruixo, Peter Zannikos, Vural Ozdemir, et al.
Page
of 4